How does ViaCyte turn pluripotent stem cells into a cell therapy for type 1 diabetes?

How does ViaCyte turn pluripotent stem cells into a cell therapy for type 1 diabetes?

ViaCyte does not deliver stem cells as a product. ViaCyte uses pluripotent stem cells as a starting material to make its cell products. In fact, ViaCyte goes to great lengths to ensure stem cells are not present in its product candidates. PEC-01 cells are called pancreatic precursor cells, but they are not stem cells.

How does ViaCyte protect the therapeutic cells from the patient’s immune system?

ViaCyte has multiple therapeutic approaches to propel clinical development. For PEC-Encap, PEC-01 cells are loaded into the Encaptra system, which is implanted under the patient’s skin (subcutaneously). The Encaptra system is designed to encapsulate and protect the cells from the immune system.

When will ViaCyte be available?

Patients in the trial will be implanted with the device for one year. The company expects to make preliminary data from the trial publicly available in the second half of 2021; the trial is projected to be completed in April 2023.

What does sernova Corp do?

Sernova is a regenerative medicine therapeutics company Sernova’s primary focus is the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease.

What is VX 880 by Vertex?

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia.

Is ViaCyte publicly traded?

ViaCyte is a privately-funded regenerative medicine company focused on cell replacement therapies for unmet medical needs.

What stem cells could be used to cure type 1 diabetes?

Type 1 diabetes patients require daily blood testing and insulin shots. Scientists have successfully used pluripotent stem cells to produce glucose-responding cells that release insulin, like beta cells.

Can regenerative medicine cure diabetes?

Despite a significant effort to produce translational results from bench to bedside, there is currently no cure for diabetes, moreover, as reviewed by Lilly et al. (1) each of the four stem cell types present significant issues.

Is sernova a good stock to buy?

The consensus among Wall Street equities research analysts is that investors should “buy” Sernova stock.

Does VX-880 use embryonic stem cells?

VX-880 is not only a potential breakthrough in the treatment of T1D, it is also one of the very first demonstrations of the practical application of embryonic stem cells, using stem cells that have been differentiated into functional islets to treat a patient, explained Doug Melton, Ph.

What is the VX-880?

VX-880 is the name of the Vertex therapy undergoing clinical testing. It uses stem cell-derived beta cells to try to restore the body’s ability to produce insulin, in combination with immunosuppressive therapy to protect the cells from rejection. These cells are administered through the portal vein in the liver.

Is type 1 diabetes completely curable?

There isn’t a cure yet for type 1 diabetes, but it’s very treatable. You may have found out you have type 1 diabetes from a routine blood test. Or you may have had sudden and severe symptoms that led to a trip to the doctor or even the emergency room.

Can ViaCyte’s pancreatic progenitor cells mature into human islet tissue?

Preliminary clinical results have shown that, following implant and when effectively engrafted, ViaCyte’s PEC-01 pancreatic progenitor cells mature into human islet tissue, including glucose-responsive insulin-secreting beta cells and other cells of the islet responsible for regulating blood glucose.

How many human cells undergo in vitro β-cell differentiation?

Here, as a step towards understanding this differentiation process, we report the transcriptional profiling of more than 100,000 human cells undergoing in vitro β-cell differentiation, and describe the cells that emerged.

Is endocrine islet cell differentiation possible in two-year explants?

At ADA 2018, data were presented from the PEC-Encap clinical trial showing that differentiation into endocrine islet cells was observed in two-year explants in regions where there was good host tissue integration and vascularization.

How are inducibly transformed pancreatic beta-cells created?

To generate an unlimited supply of human beta-cells, inducibly transformed pancreatic beta-cell lines have been created by expression of dominant oncogenes. The cell … Cell transplantation therapy for diabetes is limited by an inadequate supply of cells exhibiting glucose-responsive insulin secretion.